Abstract
Evidence came out showing that oxidative stress has a pivotal role in development and maintenance of inflammation and aberrant immune responses. Biomarkers of oxidative stress may define the proportion of oxidative damage underlying pathological conditions, and also foresee and monitor the possible efficacy of therapeutic strategies designed to control these pathologies. New compounds, which can be used as biomarkers, have been identified, and among them advanced oxidation protein products (AOPPs), formed mainly by chlorinated oxidants resulting from activity of myeloperoxidase. Our paper is aimed to review clinical evidences concerning the valuable potential of AOPPs as biomarkers of oxidative injury in development and progression of diseases and chronic conditions related to inflammatory status and immune dysregulation. These pathologies include metabolic syndrome, obesity, immune-mediated inflammatory diseases, neurodegenerative diseases, and cancer. Due to the heterogeneity of pathologies reported to be characterized by AOPP accumulation, it is evident that AOPPs are not merely a marker of neutrophil activation, but at the same time AOPPs cannot always be disease determinants. The data reported in this review corroborate the opinion that AOPPs can be successfully used to in vitro confirm the diagnosis of inflammatory and immune-mediated diseases, but at the same time evidence is that, very likely due to the way through which AOPPs are formed as well as the effect they can contribute to induce, AOPP values cannot be clearly reflective of their involvement in the pathogenesis and in the evolution of a specific disease.
Keywords: Advanced oxidation protein products, Biomarkers, Clinical studies, Oxidative stress, Myeloperoxidase, Inflammation, Immune dysregulation.
Current Medicinal Chemistry
Title:Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Volume: 23 Issue: 34
Author(s): Mariateresa Cristani, Antonio Speciale, Antonella Saija, Sebastiano Gangemi, Paola Lucia Minciullo and Francesco Cimino
Affiliation:
Keywords: Advanced oxidation protein products, Biomarkers, Clinical studies, Oxidative stress, Myeloperoxidase, Inflammation, Immune dysregulation.
Abstract: Evidence came out showing that oxidative stress has a pivotal role in development and maintenance of inflammation and aberrant immune responses. Biomarkers of oxidative stress may define the proportion of oxidative damage underlying pathological conditions, and also foresee and monitor the possible efficacy of therapeutic strategies designed to control these pathologies. New compounds, which can be used as biomarkers, have been identified, and among them advanced oxidation protein products (AOPPs), formed mainly by chlorinated oxidants resulting from activity of myeloperoxidase. Our paper is aimed to review clinical evidences concerning the valuable potential of AOPPs as biomarkers of oxidative injury in development and progression of diseases and chronic conditions related to inflammatory status and immune dysregulation. These pathologies include metabolic syndrome, obesity, immune-mediated inflammatory diseases, neurodegenerative diseases, and cancer. Due to the heterogeneity of pathologies reported to be characterized by AOPP accumulation, it is evident that AOPPs are not merely a marker of neutrophil activation, but at the same time AOPPs cannot always be disease determinants. The data reported in this review corroborate the opinion that AOPPs can be successfully used to in vitro confirm the diagnosis of inflammatory and immune-mediated diseases, but at the same time evidence is that, very likely due to the way through which AOPPs are formed as well as the effect they can contribute to induce, AOPP values cannot be clearly reflective of their involvement in the pathogenesis and in the evolution of a specific disease.
Export Options
About this article
Cite this article as:
Cristani Mariateresa, Speciale Antonio, Saija Antonella, Gangemi Sebastiano, Minciullo Lucia Paola and Cimino Francesco, Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation, Current Medicinal Chemistry 2016; 23 (34) . https://dx.doi.org/10.2174/0929867323666160902154748
DOI https://dx.doi.org/10.2174/0929867323666160902154748 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma
Current Topics in Medicinal Chemistry New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Synthesis and Evaluation of Haloacetyl, α-Bromoacryloyl and Nitrooxyacetyl Benzo[b]furan and Benzo[b]thiophene Derivatives as Potent Antiproliferative Agents Against Leukemia L1210 and K562 Cells
Letters in Drug Design & Discovery Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update
Current Drug Targets - Inflammation & Allergy Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Immunoglobulin Therapy, Myocardial Diseases and Atherosclerosis:Recent Experimental and Clinical Studies
Current Cardiology Reviews Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Monosubstituted Coumarins Inhibit Epinephrine-induced Platelet Aggregation
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Meet the Section Editor
Current Rheumatology Reviews Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism